VCL::ROS1 : A Novel ROS1 Oncogenic Fusion Detected on Next Generation Sequencing.
Anurag MehtaHimanshi DiwanShrinidhi NathanyUllas BatraManoj GuptaManoj Kumar PanigrahiDushyant KumarSakshi MattooAayushi SinghPublished in: Clinical pathology (Thousand Oaks, Ventura County, Calif.) (2024)
Advanced Non-Small Cell Lung Carcinoma (NSCLC) patients with ROS1 gene rearrangement have shown significant therapeutic responses to tyrosine kinase inhibitors approved by the US Food and Drug Administration, with approximately 40 fusion partners documented in the existing literature. Our report highlights a novel fusion partner of ROS1 that has demonstrated a conclusive response to the current standard of treatment.
Keyphrases
- drug administration
- cell death
- dna damage
- reactive oxygen species
- small cell lung cancer
- systematic review
- copy number
- transcription factor
- single cell
- dna methylation
- oxidative stress
- hepatitis c virus
- human immunodeficiency virus
- combination therapy
- epidermal growth factor receptor
- genome wide identification
- chronic myeloid leukemia
- circulating tumor
- brain metastases
- men who have sex with men